(VIANEWS) – Molina Healthcare (MOH), Novanta (NOVT), Virtus Investment Partners (VRTS) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Molina Healthcare (MOH)
20.5% sales growth and 27.53% return on equity
Molina Healthcare, Inc. provides managed healthcare services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. It operates in four segments, Medicaid, Medicare, Marketplace, and Other. The company served in across 19 states. The company was founded in 1980 and is headquartered in Long Beach, California.
Earnings Per Share
As for profitability, Molina Healthcare has a trailing twelve months EPS of $18.41.
PE Ratio
Molina Healthcare has a trailing twelve months price to earnings ratio of 17.11. Meaning, the purchaser of the share is investing $17.11 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.53%.
2. Novanta (NOVT)
12.5% sales growth and 10.83% return on equity
Novanta Inc., together with its subsidiaries, provides precision medicine and manufacturing, medical solutions, and robotics and automation solutions in the United States and internationally. The company operates through three segments: Precision Medicine and Manufacturing, Medical Solutions, and Robotics and Automation. The Precision Medicine and Manufacturing segment offers photonics-based solutions, including laser scanning, beam delivery, CO2 laser, solid state laser, ultrafast laser, and optical light engine products serving photonics-based applications for industrial processing, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; wireless technologies, video recorders, and video integration technologies for operating room integrations; optical data collection and machine vision technologies; radio frequency identification technologies; thermal chart recorders; spectrometry technologies; and embedded touch screen solutions. The Robotics and Automation segment offers optical and inductive encoders, precision motors, servo drives and motion control solutions, integrated stepper motors, intelligent robotic end-of-arm technology solutions, air bearings, and air bearing spindles. The company sells its products through its direct sales force and distributors under the Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, General Scanning, ATI Industrial Automation, Celera Motion, IMS, MicroE, Applimotion, Zettlex, Ingenia, and Westwind brands. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is headquartered in Bedford, Massachusetts.
Earnings Per Share
As for profitability, Novanta has a trailing twelve months EPS of $1.92.
PE Ratio
Novanta has a trailing twelve months price to earnings ratio of 83.93. Meaning, the purchaser of the share is investing $83.93 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.83%.
Moving Average
Novanta’s value is under its 50-day moving average of $161.87 and above its 200-day moving average of $156.39.
3. Virtus Investment Partners (VRTS)
6.9% sales growth and 14.9% return on equity
Virtus Investment Partners, Inc. is a publicly owned investment manager. The firm primarily provides its services to individual and institutional clients. It launches separate client focused equity and fixed income portfolios. The firm launches equity, fixed income, and balanced mutual funds for its clients. It invests in the public equity, fixed income, and real estate markets. The firm also invests in exchange traded funds. It employs a multi manager approach for its products. The firm employs quantitative analysis to make its investments. It benchmarks the performance of its portfolios against the S&P 500 Index. The firm conducts in-house research to make its investments. Virtus Investment Partners, Inc. was founded in 1988 and is based in Hartford, Connecticut.
Earnings Per Share
As for profitability, Virtus Investment Partners has a trailing twelve months EPS of $16.6.
PE Ratio
Virtus Investment Partners has a trailing twelve months price to earnings ratio of 13.37. Meaning, the purchaser of the share is investing $13.37 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.9%.
Sales Growth
Virtus Investment Partners’s sales growth is 9.8% for the present quarter and 6.9% for the next.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 25.2% and 14.2%, respectively.
4. Novartis AG (NVS)
5.9% sales growth and 19.83% return on equity
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Earnings Per Share
As for profitability, Novartis AG has a trailing twelve months EPS of $4.1.
PE Ratio
Novartis AG has a trailing twelve months price to earnings ratio of 22.81. Meaning, the purchaser of the share is investing $22.81 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.83%.
Moving Average
Novartis AG’s value is under its 50-day moving average of $98.76 and under its 200-day moving average of $99.54.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 1.6% and 4.9%, respectively.
Sales Growth
Novartis AG’s sales growth is negative 9.8% for the present quarter and 5.9% for the next.
Yearly Top and Bottom Value
Novartis AG’s stock is valued at $93.52 at 06:22 EST, way under its 52-week high of $108.78 and above its 52-week low of $92.19.
